on the April 1, 2026
A research team led by Dmitry Bulavin, an Inserm researcher at the Institute for Research on Cancer and Aging (Inserm/CNRS/Université Côte d’Azur), has identified a previously unknown mechanism triggered by mRNA vaccines. This research demonstrates how the immune system can develop a form of tolerance to diseases, opening up new avenues in immunology.
In a recent study, researchers from the Institute for Cancer and Aging Research, in collaboration with several international teams, reveal that mRNA vaccines do more than just trigger a conventional immune response. They can also activate a mechanism of “disease tolerance,” allowing the body to better withstand the effects of infection without necessarily eliminating the pathogen immediately.
This defense mechanism, which has yet to be fully explored, relies on a subtle modulation of immune cell activity and could pave the way for new therapeutic approaches, particularly for infectious or inflammatory diseases.
